𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Complications of acute fatty liver of pregnancy treated with activated protein C

✍ Scribed by Alexandra A. MacLean; Zoyla Almeida; Peter Lopez


Publisher
Springer
Year
2005
Tongue
English
Weight
169 KB
Volume
273
Category
Article
ISSN
0003-9128

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Fulminant hepatic failure caused by acut
✍ Samuel A. Ockner; Elizabeth M. Brunt; Steven M. Cohn; Elaine S. Krul; Douglas W. πŸ“‚ Article πŸ“… 1990 πŸ› John Wiley and Sons 🌐 English βš– 778 KB

A previously healthy 35-year-old woman was seen at 37 weeks' gestation with a 10-day history of fever, vomiting, diarrhea and malaise. Serum laboratory findings included elevation of serum bilirubin and AST, prolongation of serum prothrombin time and a positive monospot. A tentative diagnosis of acu

Postpartum plasma exchange as adjunctive
✍ James N. Martin Jr.; Christian M. Briery; Carl H. Rose; Michelle T. Owens; James πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 86 KB

## Abstract Acute fatty liver of pregnancy (AFLP) is a rare disease of progressive hepatic insufficiency and secondary systemic compromise that poses significant fetal‐maternal risk. Plasma exchange (PEX) is an effective bridge therapy to sustain liver function and enable hepatocellular regeneratio

Liver injury in acute fatty liver of pre
✍ Sathish Kumar Natarajan; Kavitha R. Thangaraj; C. E. Eapen; Anup Ramachandran; A πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 349 KB πŸ‘ 1 views

Acute fatty liver of pregnancy (AFLP) is a rare disorder which is fatal if not recognized and treated early. Delivery of the feto-placental unit results in dramatic improvement in maternal liver function, suggesting a role for the placenta. However, the mechanisms by which defects in the fetus or pl

Use of activated protein c in liver tran
✍ Laura Rinaldi; Marco Marietta; Mariano Alejandro Mignini; Lara Donno; Stefano Bu πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 82 KB

Recombinant human activated protein C (rhAPC) has been approved for use in patients with severe sepsis at high risk of death. Because of the high risk of bleeding, liver transplantation (LT) patients have been excluded from the randomized control trials that evaluated efficacy and safety of rhAPC an